Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.56 |
| ▸ | MGAM | O43451 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | SI | P14410 | 4/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 4/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | RHEB | Q15382 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8818788 | 0.82 | PIN1 (0.50) | MGAMGAASIMGAM2PARP1 | |
| SCHEMBL27961298 | 0.79 | ADORA1 (0.57) | PSMB8MGAMGAASIMGAM2 | |
| SCHEMBL4715207 | 0.78 | GAA (0.54) | PSMB8MGAMGAASIMGAM2 | |
| SCHEMBL3338846 | 0.78 | KDM4E (0.61) | GAAPIN1 | |
| SCHEMBL1170768 | 0.77 | ADORA1 (0.61) | PSMB8MGAMGAASIMGAM2 | |
| SCHEMBL14587779 | 0.75 | MGAM (0.50) | PSMB8MGAMGAASIMGAM2 | |
| SCHEMBL20982453 | 0.74 | RHEB (0.52) | GAAPIN1RHEBGSK3BXDH | |
| SCHEMBL4717701 | 0.73 | MGAM (0.48) | PSMB8MGAMGAASIMGAM2 | |
| SCHEMBL4714942 | 0.73 | PARP1 (0.52) | MGAMGAASIMGAM2PARP1 | |
| SCHEMBL19643484 | 0.72 | PKN1 (0.61) | MGAMGAASIMGAM2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | PSMB8 3058/4885MGAM 4641/4885GAA 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.